PIP-CpG

PIP-CpG is a synthetic conjugate composed of a **polyspecific integrin-binding peptide** (PIP) linked to a **CpG oligonucleotide**. The PIP moiety targets integrins overexpressed on the surface of many solid tumor cells, enabling tumor-specific delivery. The CpG component is an immunostimulatory oligonucleotide that acts as a **Toll-like receptor 9 (TLR9) agonist**, promoting potent activation of innate and adaptive anti-tumor immunity. The conjugate is designed for **systemic (intravenous) administration**, thereby overcoming the need for direct tumor injections. In preclinical murine models of aggressive breast and pancreatic cancers, intravenous PIP-CpG induced **strong infiltration of lymphocytes** (including CD8+ and CD4+ T cells and B cells), transformed the tumor microenvironment from immunosuppressive to immune-active, and resulted in notable tumor regression and durable cures in some cases. The approach leverages targeted delivery to maximize immune activation at tumor sites while minimizing off-target effects[1][2][4][5][6].

Other names

PIP + CpGPIP CpGPIP conjugated to CpGPIP-CpG conjugate